Recurrent PTPRB and PLCG1 mutations in angiosarcoma

Nature Genetics

Volumn 46, Issue 4, 2014, Pages 376-379

  Behjati, Sam ^a,b   Tarpey, Patrick S ^a   Sheldon, Helen ^c   Martincorena, Inigo ^a   Van Loo, Peter ^a,d   Gundem, Gunes ^a   Wedge, David C ^a   Ramakrishna, Manasa ^a   Cooke, Susanna L ^a   Pillay, Nischalan ^e,f   Vollan, Hans Kristian M ^a,g,h   Papaemmanuil, Elli ^a   Koss, Hans ^f,i   Bunney, Tom D ^f   Hardy, Claire ^a   Joseph, Olivia R ^a   Martin, Sancha ^a   Mudie, Laura ^a   Butler, Adam ^a   Teague, Jon W ^a   Patil, Meena ^j   Steers, Graham ^j   Cao, Yu ^k   Gumbs, Curtis ^k   Ingram, Davis ^k   Lazar, Alexander J ^k   Little, Latasha ^k   Mahadeshwar, Harshad ^k   Protopopov, Alexei ^k   Al Sannaa, Ghadah A ^k   Seth, Sahil ^k   Song, Xingzhi ^k   Tang, Jiabin ^k   Zhang, Jianhua ^k   Ravi, Vinod ^k   Torres, Keila E ^k   Khatri, Bhavisha ^e   Halai, Dina ^e   Roxanis, Ioannis ^j   Baumhoer, Daniel ^l   Tirabosco, Roberto ^e   Amary, M Fernanda ^e   Boshoff, Chris ^f,m   McDermott, Ultan ^a   Katan, Matilda ^f   Stratton, Michael R ^a   Futreal, P Andrew ^a,k   Flanagan, Adrienne M ^e,f   Harris, Adrian ^c,j   Campbell, Peter J ^a,b,n   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m PFIZER INC   (United States)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; STAT PROTEIN;

ANGIOGENESIS; ANGIOSARCOMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; FRAMESHIFT MUTATION; GENE; GENOME ANALYSIS; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPOSI SARCOMA; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PLCG1 GENE; POINT MUTATION; PRIORITY JOURNAL; PTPRB GENE; SOMATIC MUTATION; SPLICING DEFECT; TUMOR VASCULARIZATION;

ANALYSIS OF VARIANCE; BASE SEQUENCE; EXOME; HEMANGIOSARCOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPASE C GAMMA; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; RNA INTERFERENCE; SEQUENCE ANALYSIS, RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898056728     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2921     Document Type: Article

References (31)

1. Young, R.J., Brown, N.J., Reed, M.W., Hughes, D. & Woll, P.J. Angiosarcoma. Lancet Oncol. 11, 983-991 (2010
2. Fachinger, G., Deutsch, U. & Risau, W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene 18, 5948-5953 (1999
3. Winderlich, M. et al. VE-PTP controls blood vessel development by balancing Tie-2 activity. J. Cell Biol. 185, 657-671 (2009
4. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355-358 (2004
5. Guo, T. et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom. Cancer 50, 25-33 (2011
6. Dominguez, M.G. et al. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc. Natl. Acad. Sci. USA 104, 3243-3248 (2007
7. Bäumer, S. et al. Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood 107, 4754-4762 (2006
8. Broermann, A. et al. Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. J. Exp. Med. 208, 2393-2401 (2011
9. Carra, S. et al. Ve-ptp modulates vascular integrity by promoting adherens junction maturation. PLoS ONE 7, e51245 (2012
10. Hayashi, M. et al. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat. Commun. 4, 1672 (2013
11. Li, Z. et al. Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis. Proc. Natl. Acad. Sci. USA 106, 22399-22404 (2009
12. Mellberg, S. et al. Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB J. 23, 1490-1502 (2009
13. Nawroth, R. et al. VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J. 21, 4885-4895 (2002
14. Nottebaum, A.F. et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J. Exp. Med. 205, 2929-2945 (2008
15. Saharinen, P., Eklund, L., Pulkki, K., Bono, P. & Alitalo, K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 17, 347-362 (2011
16. Zhou, Q. et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am. J. Hum. Genet. 91, 713-720 (2012
17. Everett, K.L. et al. Characterization of phospholipase Cγ enzymes with gain-of-function mutations. J. Biol. Chem. 284, 23083-23093 (2009
18. Ombrello, M.J. et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366, 330-338 (2012
19. Bunney, T.D. et al. Structural and functional integration of the PLCγ interaction domains critical for regulatory mechanisms and signaling deregulation. Structure 20, 2062-2075 (2012
20. Covassin, L.D. et al. A genetic screen for vascular mutants in zebrafish reveals dynamic roles for Vegf/Plcg1 signaling during artery development. Dev. Biol. 329, 212-226 (2009
21. Lawson, N.D., Mugford, J.W., Diamond, B.A. & Weinstein, B.M. Phospholipase Cγ-1 is required downstream of vascular endothelial growth factor during arterial development. Genes Dev. 17, 1346-1351 (2003
22. Liao, H.J. et al. Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. J. Biol. Chem. 277, 9335-9341 (2002
23. Antonescu, C.R. et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 69, 7175-7179 (2009
24. Behjati, S. et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat. Genet. 45, 1479-1482 (2013
25. Tarpey, P.S. et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat. Genet. 45, 923-926 (2013
26. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010
27. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Pindel: A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009
28. Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009
29. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010
30. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910-16915 (2010
31. Greenman, C., Wooster, R., Futreal, P.A., Stratton, M.R. & Easton, D.F. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 173, 2187-2198 (2006